Australia Health Minister Greg Hunt has announced new funding to support various organisations in the clinical development of new drugs to treat rare cancers and diseases.
The A$69m ($55.10m) grant will be used for clinical trial projects involving treatments for severe conditions such as acute lymphoblastic leukaemia, multiple sclerosis, aplastic anaemia and Huntington’s disease.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will be used by University of New South Wales researchers to evaluate a vaccine for glioblastoma, while the University of Queensland’s trial will test medical cannabis’ benefits for advanced cancer.
A new preventive treatment for graft versus host disease will be investigated at Monash University in people who have had a bone marrow transplant.
Researchers at the University of Western Australia will perform a trial to compare various therapies for cystic fibrosis. This trial aims to improve care for patients suffering from the condition.
Additional trials will be conducted to assess the effectiveness and safety of aspirin in treating blood clots compared to heparin, as well as a new triple therapy regimen for rare viral-driven brain lymphomas.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHunt said in a statement: “The Turnbull government recognises the importance of clinical trials to drive new ideas and achieve new discoveries that bring improvements to quality of life and survival rates.
“Investing in health and medical research creates better health outcomes for Australians and the more than $69m ($55.10m) announced today will help ensure our nation’s strong reputation as a global leader in medical research continues.”
The minister further added that a A$10m ($7.98m) targeted grant round will be opened for research into these rare conditions with low survival rates, along with an additional A$33m ($26.35m) funding in 2018-19 to advance this research.
